Scientists have discovered genetic variants that help clarify why weight-loss drugs such as Wegovy and Mounjaro work significantly more effectively for some people than others, according to a study in the journal Nature. A examination involving 15,000 people taking these medications found that those carrying specific gene variations shed considerably more weight over roughly approximately eight months of treatment. Whilst participants lost roughly 11.7 per cent of their body weight, some shed as much as 30 per cent whilst others experienced minimal change. The findings could also help explain why certain individuals suffer severe adverse effects including nausea and vomiting. Experts suggest the genetic factors, though modest in their influence, work alongside other elements such as age, sex and ethnic background to determine how effectively these common weight-management treatments perform.
The genetic finding revolutionising obesity management
Researchers analysing data from 23andMe identified two key genetic variants that substantially affect how well weight-loss medications work. The first variant, linked to appetite regulation and digestion, is associated with greater weight loss when taking drugs like Wegovy and Mounjaro. People carrying a single copy of this variant lose approximately 0.76 kilogrammes more on average, whilst those with two copies can double that additional weight loss. The variant is particularly common among people of European ancestry, with 64 per cent carrying one copy and 16 per cent carrying two, compared to just 7 per cent of African Americans.
The second gene variant found during the study is associated with severe GI side-effects when using tirzepatide, the key component in Mounjaro. Researchers found that roughly 1 percent of people with this variant experience extremely intense vomiting—nearly 15 times more severe than common side-effects. Professor Ruth Loos from the University of Copenhagen, who commented on the research, stressed that whilst the genetic effects are fairly modest, they are comparable to other significant factors and should not be overlooked as insignificant in determining individual drug responses.
- Genetic variants affect weight loss by roughly 0.76 kilogrammes per person
- European ancestry populations demonstrate higher prevalence of weight-loss associated genes
- Second genetic variant raises risk of severe nausea and vomiting
- Genetic factors work alongside age, sex and ethnicity in determining effectiveness
How genetic factors affect drug response
The weight loss version outlined
The main genetic variant found in the research acts upon the body’s hunger control and metabolic function, directly affecting how weight-loss medications work. Individuals with this variant experience improved weight loss when taking drugs such as Wegovy and Mounjaro, with studies showing an extra 0.76 kilogrammes reduced on average versus those without the variant. The mechanism appears related to how the genes work with the medications’ hunger-suppressing action, boosting their potency in reducing hunger signals and enhancing fullness during treatment.
The impact becomes even more pronounced for those possessing two copies of the variant gene. These individuals can essentially increase their extra weight reduction, potentially gaining considerable gains over those with one copy when pursuing obesity treatment. This dual-copy genetic effect represents a meaningful distinction in outcomes, particularly important for individuals seeking greatest clinical advantage. However, researchers stress that this hereditary benefit comes with drawbacks, as carriers also suffer increased digestive adverse effects, including sickness and vomiting during treatment.
Family origins and genetic spread
The frequency of this weight-loss-related genetic variant shows considerable variation across different populations, with ancestry playing a determining role in chances of inheriting it. European ancestry populations demonstrate notably higher carrier rates relative to other ethnic groups, demonstrating genetic diversity across global populations. This disparity presents important considerations for tailored medical approaches and explaining why the effectiveness of weight-loss medications may vary among individuals from different ethnic backgrounds, which may affect treatment planning and outcome expectations.
| Population Group | Percentage Carrying Gene Variant |
|---|---|
| European ancestry (one copy) | 64% |
| European ancestry (two copies) | 16% |
| African American (one copy) | 7% |
| African American (two copies) | Data not specified |
Understanding these genetic distributions helps clarify observed differences in drug response across different populations. The notably elevated prevalence of the weight-reduction variant among individuals of European ancestry suggests they may exhibit greater benefits from these medications on average. Conversely, reduced carrier frequencies in African American communities suggest different genetic profiles that may require alternative treatment strategies or adjusted expectations regarding weight-loss outcomes with existing obesity treatments.
Beyond hereditary factors: the bigger picture
Whilst inherited differences offer valuable insights into individual drug responses, researchers stress that genetic elements constitute only one component of a considerably larger puzzle. Professor Ruth Loos notes that the genetic effect, though limited, remains “similar to other factors – and not trivial.” This indicates that many other variables influence how successfully weight-loss medications function for each person. Gender, years, daily habits, metabolism and general health condition all contribute meaningfully to results from treatment, sometimes outweighing genetic predisposition entirely.
The intricacy of personalised medicine becomes evident when examining how 15,000 trial participants experienced widely varying weight loss despite taking identical medications. Some lost 30 percent of their body weight across eight months, whilst others experienced minimal loss. This dramatic variation highlights the fact that heredity in isolation cannot determine favourable results. Lifestyle elements, adherence to treatment protocols, eating patterns and personal metabolic characteristics work together with genetic code to shape ultimate outcomes, suggesting that a nuanced approach to obesity care remains vital.
- Sex differences may impact drug metabolism and weight reduction results considerably
- Age shapes metabolic rate and medication effectiveness in observable fashion
- Ethnic background influences both genetic factors and environmental health factors
- Lifestyle choices and dietary habits prove vital despite genetic predisposition
- Individual medical conditions influence medication responses in unpredictable ways
Gender, age and ethnicity considerations
Sex differences are important factors in determining how weight-loss medications impact individuals, with growing research suggesting men and women may respond differently to drugs like Wegovy and Mounjaro. Hormonal differences, variations in body structure and varying metabolic processes between sexes could impact drug absorption and effectiveness. Age similarly impacts treatment success, as older individuals typically have slower rates of metabolism and may experience different medication processing compared to younger people, thus impacting weight loss trajectories and side-effect intensity.
Ethnicity covers both genetic and socioeconomic dimensions that influence medication outcomes beyond simple genetic inheritance. Cultural dietary patterns, healthcare access, the affordability of medications and lifestyle choices vary significantly across ethnic groups, all affecting how well weight-loss medications work. Researchers recognise that comprehending these overlapping factors demands thorough examination beyond genetic investigation by itself, ensuring that upcoming therapeutic recommendations cater to diverse populations justly and successfully.
From research findings to clinical practice
The discovery of genetic variants affecting weight-management medication effectiveness opens exciting opportunities for tailored medical treatment in weight management. Translating these laboratory findings into clinical practice requires careful consideration of how genetic screening could be integrated into NHS prescription guidelines and private healthcare pathways. Healthcare professionals may eventually use genetic screening to predict which patients will respond most favourably to specific medications, possibly enhancing clinical results and reducing unnecessary side-effects. However, implementing such testing across the system presents logistical and financial obstacles that the health service must address in a structured manner.
Current obesity treatment remains largely one-size-fits-all, with patients receiving identical medications regardless of their genetic makeup. As genetic understanding deepens, clinicians could tailor prescriptions to individual genetic profiles, maximising weight loss whilst reducing unwanted side effects. This shift towards precision medicine requires funding in genetic testing infrastructure, clinician education programmes and revised treatment protocols. The research indicates that whilst genetic factors contribute modestly, their identification alongside monitoring of other variables could significantly enhance treatment efficacy and client outcomes across diverse populations.
The personalised medicine potential
Precision medicine represents a fundamental shift from conventional treatment guidelines towards tailored patient care based on genetic and physical traits. By establishing which individuals have beneficial genetic variants, clinicians could improve drug choice and treatment dosages, consequently improving weight loss outcomes whilst decreasing nausea and vomiting complications. This approach promises more efficient resource use, improved patient experiences and increased certainty in obesity management across the NHS and private healthcare providers.
- Genetic screening can predict individual drug response patterns accurately
- Personalised dosing regimens may decrease adverse side-effects considerably
- Precision approaches optimise treatment satisfaction and clinical outcomes substantially
What this means for service users now
For the vast numbers of people presently using weight-loss medications like Wegovy and Mounjaro, these genetic discoveries offer valuable understanding into why their outcomes vary so dramatically. Whilst genetic influences represent only a limited effect on treatment success, they work in conjunction with other important considerations including sex, age and cultural origin to shape personal results. Understanding these patterns helps account for why some patients see substantial weight losses of 30 per cent or more, whilst others see minimal results despite taking the same drugs. This knowledge confirms the frustration many patients experience when treatments fail to deliver expected benefits, suggesting physiological elements rather than personal failure play a crucial role.
Currently, the NHS and independent healthcare providers dispense weight-loss drugs without genetic testing, meaning patients are given standardised treatment irrespective of their individual genetic profile. The majority of individuals taking these drugs remain unaware whether they have genetic variants that could predict their response or susceptibility to side-effects such as intense nausea. Whilst genetic testing is not currently widely available through the NHS, this research offers a basis for future bespoke treatment methods. Patients talking through treatment options with medical professionals can now understand that their genetic profile may influence outcomes, potentially encouraging more informed conversations about realistic expectations and personal risk considerations before beginning medication.